Last reviewed · How we verify
single infusion of Rituximab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
single infusion of Rituximab (single infusion of Rituximab) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| single infusion of Rituximab TARGET | single infusion of Rituximab | Assistance Publique - Hôpitaux de Paris | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- single infusion of Rituximab CI watch — RSS
- single infusion of Rituximab CI watch — Atom
- single infusion of Rituximab CI watch — JSON
- single infusion of Rituximab alone — RSS
Cite this brief
Drug Landscape (2026). single infusion of Rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/single-infusion-of-rituximab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab